Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Immunosuppressive therapies, such as anti-thymocyte globulin and cyclosporine, may
improve bone marrow function and increase blood cell counts. PURPOSE: This phase II trial is
studying how well giving anti-thymocyte globulin together with cyclosporine as first-line
therapy works in treating patients with severe aplastic anemia.